S&P Futures
4,054.75 -29.50 (-0.72%) Dow Futures
33,860.00 -186.00 (-0.55%) Nasdaq Futures
12,099.75 -122.50 (-1.00%) Russell 2000 Futures
1,904.90 -14.60 (-0.76%) Crude Oil
79.31 -0.37 (-0.46%) Gold
1,938.70 -6.90 (-0.35%)
Atara Biotherapeutics, Inc. (AT2.F)
Chart Events
Performance Outlook
| Previous Close | 4.6670 |
| Open | 4.7780 |
| Bid | 4.7590 x N/A |
| Ask | 4.8870 x N/A |
| Day's Range | 4.4750 - 4.6670 |
| 52 Week Range | 2.6730 - 13.4950 |
| Volume | |
| Avg. Volume | 30 |
| Market Cap | 469.983M |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4650 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AT2.F
Related Research
- Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THOUSAND OAKS, Calif., January 13, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired emp
- Business Wire
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., January 04, 2023--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Fr
- Motley Fool
3 Under-the-Radar Biotech Stocks to Buy in 2022
Beam Therapeutics is different from many CRISPR-editing biotechs in that it uses ex-vivo base cell editing instead of nuclease cell editing. Beam stock is down more than 48% so far this year, but the company has a growing pipeline that shows promise. Its lead therapy is BEAM-101 to treat various blood diseases, including sickle cell disease (SCD) and beta thalassemia.
